Home > Healthcare > Healthcare IT > Artificial Intelligence > Cardiac AI Monitoring and Diagnostics Market

Cardiac AI Monitoring and Diagnostics Market Trends

Report ID: GMI8858
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Cardiac AI Monitoring and Diagnostics Market Trends

The rising prevalence of cardiovascular diseases (CVDs) is a driving factor for the growth of the market. CVDs including coronary artery disease, heart failure, arrhythmias, and stroke are among the leading causes of morbidity and mortality worldwide.

For instance, according to the National Library of Medicine, in 2024, coronary artery disease (CAD) accounts for approximately 6,10,000 deaths annually (estimated 1 in 4 deaths) and is the leading cause of mortality in the U.S. Also, it is the third leading cause of mortality worldwide and is associated with 17.8 million deaths annually.
AI algorithms can analyze large volumes of patient data including medical history, genetic information, and real-time physiological data from wearable devices to identify early signs of cardiovascular diseases. Early detection allows for timely intervention and management, potentially preventing serious complication.
Additionally, it facilitates the analysis of large-scale clinical datasets to identify novel cardiac biomarkers which estimated to reach 31.2 billion by 2032, genetic associations, and treatment targets for cardiovascular diseases. This accelerates the pace of research and innovation in cardiology, leading to the development of new therapies, diagnostic tools, and preventive strategies, thereby escalating the growth of the market.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for cardiac AI monitoring and diagnostics recorded USD 984.7 million in 2023 and is expected to register 26.9% CAGR from 2024 to 2032, owing to the growing prevalence of cardiovascular diseases, and rising focus on precision medicine.

The hardware segment of the cardiac AI monitoring and diagnostics industry is expected to accumulate USD 5 billion by 2032, due to the enhanced computational power of hardware tools like advanced processors, enabling real-time analysis of cardiac data.

North America industry accounted for USD 399.2 million in revenue in 2023 and is expected to expand at notable CAGR from 2024 to 2032, on account of the high rates of obesity, sedentary lifestyles, and an aging population.

CardiAI, Cleerly, Inc., DiA Imaging Analysis, HeartVista Inc., IDOVEN, Koninklijke Philips N.V., RSIP Vision, Tempus, Ultrasight, Ultromics Limited, Viz.ai, Inc. are some of the major cardiac AI monitoring and diagnostics companies worldwide.